However, overactivation of the mineralocorticoid receptor (MR) and elevated aldosterone levels are implicated in the ... Pretreatment with esaxerenone reversed the effect of aldosterone, whereas ...

The Danish pharma bought the nonsteroidal mineralocorticoid receptor antagonist, called ocedurenone, from KBP Biosciences a ...

Finerenone further reduces albuminuria in patients already on triple therapy for CKD with type 2 diabetes (SGLT2i, GLP-1 RA, ...

New research findings on the nonsteroidal mineralocorticoid receptor antagonist finerenone are summarized in a short video.

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.

MR = Mineralocorticoid receptor; PR = Progesterone receptor. The relative binding affinity (%) of the main progestins discussed in this paper for the different steroid receptors is indicated.

Background: Standard pharmacotherapy for patients with heart failure with reduced ejection fraction (HFrEF) comprises “quadruple therapy” with a renin–angiotensin system inhibitor, a β-blocker, a ...

The orally-active drug, a non-steroidal mineralocorticoid receptor antagonist (nsMRA), is currently in the phase 3 trial CLARION-CKD in patients with uncontrolled hypertension – in other words ...

Glucagon-like peptide-1 (GLP-1) receptor agonists, which can slow gastric emptying and increase the risk of retained gastric contents, are increasingly prescribed for ...

Although finerenone has kidney protective effects in patients with chronic kidney disease and type 2 diabetes, it does not appear to slow kidney function decline in patients with heart failure with ...

Yee: ALKS 2680 has a novel mechanism. It targets the orexin 2 receptors, and we know that the orexin pathway is very important in terms of maintaining wakefulness. So other treatment that we ...